Stay updated with breaking news from Deep Lens. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Synthetica Bio, a privately held healthcare technology company developing an enterprise-grade, generative artificial intelligence (GenAI)...
/PRNewswire/ -- The "AI-based Clinical Trial Solutions For Patient Matching Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Application;...
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
The two companies attracted investments from F-Prime Capital, GV, LUX Capital and Mubadala Capital.